Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
Benjamin Kearns, Katy Cooper, Anna Cantrell, Chloe Thomas School of Health and Related Research, The University of Sheffield, Sheffield, UKCorrespondence: Benjamin Kearns Email b.kearns@sheffield.ac.ukPurpose: Cardiovascular and metabolic adverse events are costly to treat, and their incidence is in...
Enregistré dans:
Auteurs principaux: | Kearns B, Cooper K, Cantrell A, Thomas C |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e5ce207ca0524f62a7e45bc7d7d3a3d3 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
par: Pu C, et autres
Publié: (2020) -
Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
par: Rachael K. Blackman, et autres
Publié: (2022) -
Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia
par: Escamilla R, et autres
Publié: (2018) -
Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
par: Fitzgerald HM, et autres
Publié: (2021) -
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
par: Dayabandara M, et autres
Publié: (2017)